» Articles » PMID: 36304007

Integrating Pre-Exposure Prophylaxis Delivery in Public Health Family Planning Clinics: Lessons Learned From a Programmatic Implementation Project in Kenya

Overview
Date 2022 Oct 28
PMID 36304007
Authors
Affiliations
Soon will be listed here.
Abstract

Sexually active African women are a priority population for HIV prevention due to the disproportionately high frequency of new HIV infections. Family planning (FP) clinics offer an already trusted platform that can be used to reach women for HIV prevention services, including pre-exposure prophylaxis (PrEP). In the recent PrEP Implementation in Young Women and Adolescent (PrIYA program), we piloted PrEP implementation in FP clinics in Kisumu, Kenya, and demonstrated that it was possible to integrate PrEP provision in FP systems with a program-dedicated staff. In this perspective, we describe experiences and strategies employed to introduce PrEP implementation in FP clinics and lessons learned. We identified the following lessons for PrEP introduction in FP clinics in Kenya: (1) possible to integrate and generate high enthusiasm for PrEP delivery in FP clinics but persistence on PrEP is a challenge, (2) involvement of national and regional stakeholders is critical for buy-in, contextualization, and sustainability, (3) delivery models that do not integrate fully with existing staff and systems are less sustainable, (4) creatinine testing at PrEP initiation may not be necessary, (5) fully integrated HIV and FP data systems need to be developed, and (6) incorporating implementation science evaluation is important to understand and document effective implementation strategies. In summary, integration of HIV prevention and FP services provides an opportunity to promote one-stop women-centered care efficiently. However, a broader focus on delivery models that utilize existing staff and novel strategies to help women identify their own risk for HIV are needed to ensure greater success and sustainability.

Citing Articles

Patterns of PrEP continuation and coverage in the first year of use: a latent class analysis of a programmatic PrEP trial in Kenya.

Mugwanya K, Palayew A, Schaafsma T, Irungu E, Bukusi E, Mugo N J Int AIDS Soc. 2023; 26(7):e26137.

PMID: 37403405 PMC: 10320042. DOI: 10.1002/jia2.26137.


Effect of 6-Month HIV Preexposure Prophylaxis Dispensing With Interim Self-testing on Preexposure Prophylaxis Continuation at 12 Months: A Randomized Noninferiority Trial.

Ortblad K, Bardon A, Mogere P, Kiptinness C, Gakuo S, Mbaire S JAMA Netw Open. 2023; 6(6):e2318590.

PMID: 37318803 PMC: 10273023. DOI: 10.1001/jamanetworkopen.2023.18590.


"PrEP should be available all the time and everywhere": A qualitative assessment of family planning and PrEP integration in Lesotho.

Nonyana N, Matete M, Lebetkin E, Yacobson I, Strachan M, Ramapepe M Front Reprod Health. 2022; 4:981845.

PMID: 36303649 PMC: 9580645. DOI: 10.3389/frph.2022.981845.

References
1.
Abuna F, Kinuthia J, Lagat H, Mugwanya K, Dettinger J, Begnel E . A Field Evaluation of Point-of-Care Creatinine Testing Within a Large PrEP Implementation Program in Western Kenya. J Acquir Immune Defic Syndr. 2019; 82(1):e8-e10. DOI: 10.1097/QAI.0000000000002109. View

2.
Kinuthia J, Pintye J, Abuna F, Mugwanya K, Lagat H, Onyango D . Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2019; 7(1):e38-e48. PMC: 11498332. DOI: 10.1016/S2352-3018(19)30335-2. View

3.
Mugwanya K, Wyatt C, Celum C, Donnell D, Mugo N, Tappero J . Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med. 2014; 175(2):246-54. PMC: 4354899. DOI: 10.1001/jamainternmed.2014.6786. View

4.
Pintye J, Kinuthia J, Roberts D, Wagner A, Mugwanya K, Abuna F . Brief Report: Integration of PrEP Services Into Routine Antenatal and Postnatal Care: Experiences From an Implementation Program in Western Kenya. J Acquir Immune Defic Syndr. 2018; 79(5):590-595. PMC: 6500722. DOI: 10.1097/QAI.0000000000001850. View

5.
Mugwanya K, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A . Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr. 2016; 71(4):374-80. PMC: 4770857. DOI: 10.1097/QAI.0000000000000868. View